Stages Archives - WuXi Biology

DEL and Display Technologies Empower Discovery of Peptide Drugs

In recent years, peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages,...

D2B: Direct-to-Biology Platform

Looking for a solution to accelerate your drug discovery processes? WuXi AppTec’s integrated Direct-to-Biology (D2B) platform is a cost-effective and...

Advanced Screening Methods for Better Drug Targets

From Undruggable to Actionable: Advanced Screening Methods for Better Drug Targets Introduction: Identifying a high-quality drug target is the cornerstone...

CTHRC1 as a Novel Candidate for Neurodevelopmental Disorders

Cognitive dysfunction affects over 50 million individuals worldwide, with Alzheimer’s disease (AD) representing two-thirds of cases. Due to the complexity...

Fully Automated HTS Platform for Screening Diverse Targets

High-throughput screening (HTS) remains a foundational technology in early drug discovery, responsible for identifying approximately one-third of today’s clinical candidates....

Webinar: Target Deconvolution and Tractability Assessment

Target deconvolution, particularly when paired with proteomics techniques, plays a crucial role in drug discovery and target identification. By using...

Navigating the ADC Development Pathway

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....

Innovative Technologies in Early Drug Discovery

In this webinar, WuXi AppTec scientists discuss the latest innovative technologies and products in early-stage drug discovery. Viewers will gain...

DELvision: A Protein-DEL Interaction Database

Currently, there is a lack of efficient experimental strategies to collect high-quality proteome-level data for protein-ligand interactions (PLIs). At DEL...

Knowledge Library